Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00679081 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of CelTx(TM) (Apligraf®) in the Treatment of Gingival Recession Requiring Root Coverage
A Phase 1 study, sponsored by Organogenesis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00679081 is a Phase 1 study that was terminated before completion, run by Organogenesis. The registered enrollment target is 15 participants.
The verdict
NCT00679081, a Phase 1 study, was terminated before completion, sponsored by Organogenesis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate CelTx as an alternative to tissue from the palate in the treatment of subjects with Miller Class I or II recession defects who desire root coverage. It is anticipated that this study will demonstrate that CelTx is a safe alternative to palatal tissue and demonstrate potential to enhance oral soft tissue regeneration and wound healing.
Interventions
- DEVICE CelTx
- OTHER Autologous sub-epithelial connective tissue graft
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00679081
The ClinicalTrials.gov registry entry for NCT00679081 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Organogenesis, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CelTx is the first listed.
NCT00679081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00679081 about?
NCT00679081 is a clinical study titled "A Pilot Study of CelTx(TM) (Apligraf®) in the Treatment of Gingival Recession Requiring Root Coverage". The purpose of this study is to evaluate CelTx as an alternative to tissue from the palate in the treatment of subjects with Miller Class I or II recession defects who desire root coverage. It is anticipated that this study will demonstrate that CelTx is a safe alternative to palatal tissue and demo...
What is the current status of trial NCT00679081?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2008-05. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00679081?
The interventions under investigation include: CelTx (DEVICE), Autologous sub-epithelial connective tissue graft (OTHER).
Who is sponsoring clinical trial NCT00679081?
This trial is sponsored by Organogenesis, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.